Dendreon's Date With Destiny
Updated from March 8
Dendreon (DNDN) will take its prostate cancer drug Provenge in front of an FDA advisory panel on March 29. This is going to be a major stock-moving event, and for me, at least, the outcome is very much in the air.
I said as much in a column last week, but I also promised to dig deeper into the story. Having done so, here's a discussion of the issues surrounding Provenge's date with the FDA.
What is Provenge?You might have heard Provenge referred to as a prostate cancer vaccine. That's an easy descriptor, but it's not entirely accurate because the drug isn't an inoculation and therefore won't prevent you from getting cancer. What Provenge does is prime your immune system to recognize a certain protein expressed on prostate cancer cells. When your immune system encounters this protein they recognize it as foreign and it attacks. In this way, Provenge is really an "immunotherapy." Neat stuff, has there ever been an immunotherapy approved by the FDA? No, that's what makes Dendreon such an interesting story. Many other "cancer vaccine" companies have tried but failed. Dendreon is the first to seek FDA approval. What's going to happen at the FDA advisory panel meeting on March 29? I've heard that this panel should be favorably inclined to like Provenge. Isn't this a good development for Dendreon? Yes and no. The FDA's Cell, Tissue and Gene Therapy Advisory Committee that will review Provenge is a more hospitable environment for Dendreon than the agency's cancer division, known to be real data-driven sticklers. As analysts at LifeTech Research first pointed out in a Dendreon report, the CTGT folks are no pushovers, especially the woman who runs the division, Celia Witten -- she is tough. When she was a director in the FDA's medical device division, she led the effort to reject Cyberonics' (CYBX) neuro-stimulation device for depression, overturning the positive recommendation of an advisory committee panel.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV